09995 REMEGEN
- 27.850
- -2.650-8.69%
REMEGEN News
Changes in Hong Kong stocks | Rongchang Biotech (09995) fell more than 7%, and the loss in the first quarter increased to 349 million yuan year-on-year, and previously announced a planned increase of 2.55 billion yuan
Rongchang Biotech (09995) fell by more than 7%. As of press release, it was down 7.54% to HK$28.2, with a turnover of HK$483.39 million.
榮昌生物：2024年第一季度報告
Rongchang Biotech (688331.SH) announced first-quarter results with a net loss of 349 million yuan
Rongchang Biotech (688331.SH) disclosed its report for the first quarter of 2024. The company achieved operating income during the reporting period...
榮昌生物：2023 年度報告
Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism
Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.
Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 4%, and the company plans to increase nearly 2.6 billion yuan. The agency says there are many catalysts this year
Rongchang Biotech (09995) rose more than 4%. As of press release, it rose 4.76% to HK$29.7, with a turnover of HK$126.792 million.
Hong Kong bullish stocks this week | 80% increase in the month! TCL Electronics surged more than 16% this week; CRRC surged nearly 11% the day after
Benefiting from the acceleration of nuclear power approval, CGN's stock price has been rising for five consecutive days; coal supply and demand continued to be tight, and Mongolian coking coal increased by more than 11% during the week.
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | April 18
According to data disclosed on April 17, 2024, Zhaojin Mining (01818.HK), Laikai Pharmaceutical-B (02105.HK), and Vanke Enterprise (02202.HK) accounted for the largest share increases of 1.23%, 0.86%, and 0.84%, respectively; Follett Glass (06865.HK), Beijing Fund Finance International (01468.HK), and Rongchang Biotech (09995.HK) Hong Kong Stock Connect had the largest share losses, with decreases of -0.90%, -0.52%, and -0.52%, respectively.
Lu Tai A (000726.SZ): Currently holds about 3.91 million shares of Rongchang Biotech, and there are no plans to reduce its holdings
Gelonghui, April 17 | Lu Tai A (000726.SZ) said on the investor interactive platform that the company currently holds about 3.91 million shares of Rongchang Biotech and has no plans to reduce its holdings. The fund jointly set up by the company and Haojun Investment has an investment of about 50 million yuan.
Rongchang Biotech (09995.HK) plans to hold a board meeting on April 26 to approve the first quarter results
Gelonghui, April 16, 丨 Rongchang Biotech (09995.HK) announced that the company will hold a board meeting on April 26, 2024 (Friday) to consider and approve (among other things) the unaudited first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their publication.
榮昌生物：董事會召開日期
How many difficulties are there on the way to the Rongchang Biotech Plan's fixed increase of over 2 billion yuan
“Investor Network” Cai Jun Rongchang Biotech (688331.sh, hereinafter referred to as the “Company”) has reached another critical point. At the end of March, the company announced a fixed increase plan. It plans to raise up to 2.55 billion yuan, all of which will be used for “new drug research and development projects”, including RC18, RC48, RC28, RC88, RC148, and RC198. Around the same time, the company also released its 2023 annual report. Up to now, the company's core marketed products include taitacip, verdicitumab, etc. During the reporting period, the company's revenue increased by 40.26% year on year, net profit to mother - 1.51 billion yuan, loss
CCB International: Maintaining Rongchang Biotech's (09995.HK) “Outperform the Market” rating and raising the target price to HK$34
CCB International released a research report stating that while maintaining Rongchang Biotech (09995.HK)'s “outperforming the market” rating, the target price was raised by 30.8% from HK$26 to HK$34. The company's 2023 results were basically in line with expectations, and the fourth quarter of 2023 results exceeded CCB's expectations. Overall net losses for the fourth quarter of 2023 and 2023 reached 1.5 billion yuan (same below) and 481 million yuan respectively. Excluding equity incentive costs, net losses would be $1.4 billion and $365 million respectively, which is less than anticipated.
Changes in Hong Kong stocks | Rongchang Biotech (09995.HK) rose more than 9% in the afternoon, rapid release of core products, and the company has many catalysts this year
Rongchang Biotech (09995.HK) rose more than 9% in the afternoon. As of press release, it rose 7.9% to HK$33.45, with a turnover of HK$68,8303 million.
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | April 11
According to data disclosed on April 10, 2024, CNOOC Oilfield Services (02883.HK), Southern Hang Seng Technology (03033.HK), and Zhonglian Heavy Industries (01157.HK) Hong Kong Stock Connect held the largest share gains, increasing by 1.41%, 0.87%, and 0.68% respectively; Saisheng Pharmaceutical (06600.HK), Oriental Selection (01797.HK), and Rongchang Biotech (09995.HK) Hong Kong Stock Connect shares decreased the most, with decreases of -0.77% and -0.71%, respectively -0.60%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Beijing has brought great benefits to innovative drugs!
In the middle of the night of April 7, the Beijing Municipal Medical Security Administration suddenly issued a “Notice on Public Consultation on the “Certain Measures to Support the High-Quality Development of Innovative Medicines by 9 Departments Including the Beijing Municipal Medical Security Administration (2024) (Draft for Comments)”. The public submission period for this consultation draft is only 3 working days. The first section of the clinical study clearly proposed reducing the overall time required to start a clinical trial to 28 weeks.
Guoxin Securities released a research report on April 8 stating that it gave Rongchang Biotech (688331.SH) an increase in its holdings. The main reasons for the rating include: 1) commercialization of core products is progressing well; 2) clinical promoti
Guoxin Securities released a research report on April 8 stating that it gave Rongchang Biotech (688331.SH) an increase in its holdings. The main reasons for the rating include: 1) commercialization of core products is progressing well; 2) clinical promotion of multiple indications of tetracipid in China and the US; 3) expansion of verdicitumab indications to front-line treatment. (Mainichi Keizai Shimbun)
Rongchang Biotech (9995.HK): Strong revenue growth, clinical progress continues to be steady
Core view The company achieved revenue of 1,083 billion yuan in 2023, an increase of 40.26% over the same period last year, and achieved strong growth on the revenue side. The company has many catalysts in 2024, Taitaxip Overseas SLE Phase 3
Rongchang Biotech (688331): Sales of core products continue to grow, clinical development progresses in an orderly manner
Sales of core products continued to grow. Rongchang Biotech achieved revenue of 1,083 million yuan (+40.3%) in 2023, and revenue of 313 million yuan (+54.8%) in a single quarter. Revenue maintained rapid growth; the company maintained a net loss for the whole year
Analysis
Price Target
No Data
